Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 21,055 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 21,055 shares of Neumora Therapeutics stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $1.60, for a total transaction of $33,688.00. Following the completion of the transaction, the insider owned 48,750 shares of the company’s stock, valued at $78,000. The trade was a 30.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Daljit Singh Aurora also recently made the following trade(s):

• On Thursday, August 20th, Daljit Singh Aurora sold 66,711 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.51, for a total transaction of $100,733.61.
• On Thursday, August 20th, Daljit Singh Aurora sold 67,741 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.51, for a total value of $102,288.91.
• On Friday, August 21st, Daljit Singh Aurora sold 20,553 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total value of $32,679.27.
• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total transaction of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total transaction of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.59, for a total value of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.58, for a total value of $53,975.96.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock traded up $0.12 on Friday, hitting $1.63. 498,604 shares of the company traded hands, compared to its average volume of 765,644. Neumora Therapeutics, Inc. has a 12-month low of $0.83 and a 12-month high of $3.65. The firm’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $2.10. The company has a market cap of $306.28 million, a P/E ratio of -1.33 and a beta of 2.75. The company has a current ratio of 4.50, a quick ratio of 5.09 and a debt-to-equity ratio of 1.19.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Friday, August 14th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Analysts expect that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on NMRA. Weiss Ratings cut Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. Needham & Company LLC decreased their target price on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Royal Bank Of Canada lowered their price target on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Mizuho dropped their target price on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, June 18th. Finally, HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.57.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently modified their holdings of NMRA. HBK Sorce Advisory LLC purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at about $26,000. Hsbc Holdings PLC bought a new position in shares of Neumora Therapeutics during the 4th quarter valued at $27,000. Virtu Financial LLC bought a new position in shares of Neumora Therapeutics in the 3rd quarter worth approximately $31,000. Fred Alger Management LLC bought a new position in Neumora Therapeutics in the 4th quarter worth $40,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Neumora Therapeutics during the 2nd quarter valued at approximately $41,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.